TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to cut deaths and heart crises in rare amyloid heart disease
Disease control Recruiting nowThis study tests an investigational drug called nucresiran in about 1250 adults with a rare heart condition called ATTR amyloidosis with cardiomyopathy. The goal is to see if the drug can lower the risk of death and serious heart events compared to a placebo. Participants will re…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
Global study tracks Real-World impact of new heart drug
Knowledge-focused Recruiting nowThis study will follow about 2000 adults with a rare heart condition called ATTR-CM, where abnormal proteins build up in the heart. Participants are starting treatment with the drug vutrisiran or another approved therapy. Researchers will track symptoms, quality of life, and heal…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated May 07, 2026 18:38 UTC